- Oncology gross orders up 5%, supported by gains across all regions
- Booked three proton orders during the quarter
- Backlog of $3.25 billion; up 6%, led by a 7% increase in Oncology Systems
- Gross margin up 19 basis points to 44.3% driven by increased service revenue mix and supply chain efficiencies
- GAAP net earnings per diluted share from continuing operations of $0.98, $1.04 non-GAAP
PALO ALTO, Calif., July 26, 2017 /PRNewswire/ -- Varian Medical Systems (NYSE:VAR), the world’s leading manufacturer of medical devices and software for treating and managing cancer, today announced its third-quarter fiscal 2017 operating results. All comparisons in this announcement are year-over-year unless noted otherwise.
Summary
($ in millions except EPS) | Q3 2017 | Q3 2016 | YTD | YTD |
Revenues | $662.4 | $642.9 | $1,929.2 | $1,873.9 |
Growth Reported | 3.0% | 3.0% | ||
Growth Constant Currency | 4.0% | 4.0% | ||
Gross Margin | 44.3% | 44.1% | 43.8% | 42.4% |
GAAP Net Earnings (1) | $90.6 | $81.9 | $174.4 | $231.0 |
GAAP Net Earnings Per Diluted Share (1) | $0.98 | $0.86 | $1.86 | $2.39 |
Net Cash Provided by Operating Activities | $155.1 | $95.2 | $269.4 | $204.3 |
Non-GAAP Net Earnings (1) (2) | $96.2 | $95.4 | $234.5 | $257.2 |
Non-GAAP Net Earnings per Diluted Share (1) (2) | $1.04 | $1.00 | $2.51 | $2.66 |
(1) | GAAP Net Earnings and Earnings Per Share and Non-GAAP Net Earnings and Non-GAAP Earnings Per Share refer only to continuing operations. GAAP and Non-GAAP Earnings Per Share, for the quarter and year-to-date period ended June 30, 2017, were calculated considering diluted shares of 92.4 million and 93.5 million, respectively. For the quarter and year-to-date period ended June 30, 2016, the number of diluted shares was 95.4 million and 96.5 million, respectively. |
(2) | Non-GAAP Net Earnings and Non-GAAP Earnings Per Share are defined as GAAP Net Earnings and GAAP Earnings Per Share adjusted to exclude the amortization of intangible assets, acquisition-related expenses and benefits, restructuring and impairment charges and significant litigation charges or benefits and legal costs. |
“I am pleased with our solid execution this quarter,” said Dow Wilson, CEO of Varian Medical Systems. “We extended our industry leadership with the successful launch of the new Halcyon treatment system at the ESTRO show in May, gross orders for our Oncology business grew five percent and we booked three proton orders during the quarter. Importantly, we executed well against our operational priorities, including improved operating profitability and working capital discipline.”
Revenues in the quarter included $46 million from a proton order received from the Georgia Proton Therapy Center, which contributed approximately $0.10 of EPS.
The company ended the quarter with $658 million in cash and cash equivalents and $364 million of debt. Net cash provided by operating activities was healthy at $155 million in the quarter, supported by strong cash collections, and $269 million year-to-date, up $65 million. During the quarter, the company invested $47 million to repurchase 500,000 shares of common stock.
Oncology Systems Segment
In the quarter, Oncology gross orders were $708 million, up 5 percent in dollars and in constant currency. Gross orders in the Americas increased 3 percent in dollars and in constant currency, supported by 3 percent growth in North America. In EMEA, gross orders rose 2 percent and 5 percent in dollars and in constant currency, respectively, and in APAC gross orders rose 13 percent in dollars and in constant currency. Revenues for the segment totaled $594 million, down 2 percent in dollars and 1 percent in constant currency with the decline driven largely by increased backlog mix from emerging markets causing the backlog conversion cycle to lengthen.
“Our Oncology business grew gross orders in every region, with notable contributions from our service and software businesses and the first orders for our new Halcyon treatment system,” said Wilson. “Orders in our China business grew by over 30 percent as we extended our leadership in this key market.”
Particle Therapy Segment
In the quarter, the company booked orders totaling $122 million, including an order to equip a multi-room facility at the Georgia Proton Therapy Center in Atlanta. Orders for single-room ProBeam® Compact systems at the University of Pennsylvania and in Thailand were also booked during the quarter. Revenues for the Particle Therapy business almost doubled in the quarter to $68 million.
“We continued to win orders for our single-room system as the proton market transitions to smaller facilities, demonstrating our increasing competitiveness in this field,” said Wilson. “We were able to book the Georgia Proton Therapy Center order after the customer carried out a successful bond issuance.”
Outlook
Fourth quarter revenue growth is now expected to be flat to down slightly. For Q217 to Q417, revenue growth is expected to be between 2 and 3 percent, including the impact of proton revenues. Non-GAAP diluted earnings per share from continuing operations are expected to be in the range of $1.15 to $1.23 for the fourth quarter and between $3.08 and $3.16 for Q217 to Q417, including the earnings contribution of the proton business.
Please refer to “Discussion of Non-GAAP Financial Measures” below for a description of items excluded from expected non-GAAP earnings.
Investor Conference Call
Varian Medical Systems is scheduled to conduct its third quarter fiscal year 2017 conference call at 2 p.m. PT today. To hear a live webcast or replay of the call, visit the investor relations page on our company’s web site at www.varian.com/investor where it will be archived for a year. To access the call via telephone, dial 1-877-869-3847 from inside the U.S. or 1-201-689-8261 from outside the U.S. The replay can be accessed by dialing 1-877-660-6853 from inside the U.S. or 1-201-612-7415 from outside the U.S. and entering confirmation code 13664498. The telephone replay will be available through 5 p.m. PT, Friday, July 28, 2017.
About Varian Medical Systems
Varian Medical Systems focuses energy on saving lives and is the world’s leading manufacturer of medical devices and software for treating and managing cancer. Headquartered in Palo Alto, California, Varian employs approximately 6,600 people at sites around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.
FOR INFORMATION CONTACT:
Gary Bischoping (650) 424-5691
gary.bischoping@varian.com
Neil Madle (+44) 7786 526068
neil.madle@varian.com
Forward-Looking Statements
Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry or market outlook, including growth drivers; the company’s future orders, revenues, or earnings growth or other financial results; and any statements using the terms “believe,” “expect,” “promising,” “outlook,” “should,” “will” or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company’s actual results to differ materially from those anticipated. Such risks and uncertainties include global economic conditions; currency exchange rates and tax rates; the impact of the Affordable Health Care for America Act (including excise taxes on medical devices) and any further healthcare reforms (including changes to Medicare and Medicaid), and/or changes in third-party reimbursement levels; demand for and delays in delivery of the company’s products; the company’s ability to develop, commercialize and deploy new products; the company’s ability to meet Food and Drug Administration (FDA) and other regulatory requirements, regulations or procedures; changes in regulatory environments; challenges associated with commercializing the company’s particle therapy business; challenges to public tender awards and the loss of such awards or other orders; the effect of adverse publicity; the company’s reliance on sole or limited-source suppliers; the company’s ability to maintain or increase margins; the impact of competitive products and pricing; the company’s assessment of the goodwill associated with its particle therapy business; the potential loss of key distributors or key personnel; and the other risks listed from time to time in the company’s filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.
To read full press release, please click here.
